secwatch.observer — SEC 8-K summary
======================================

Issuer:     Certara, Inc. (CERT)
CIK:        0001827090
Form:       8-K
Filed at:   2024-07-09T23:59:59+00:00
Accession:  0001104659-24-078581
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Certara signs definitive agreement to acquire Chemaxon; reiterates 2024 guidance
--------------------------------------------------------------------------------

- Definitive agreement to acquire Chemaxon, a cheminformatics software provider; no deal value disclosed.
- Transaction expected to close in H2 2024, subject to regulatory approval and customary conditions.
- Chemaxon expected to generate >$20M software revenue in 2024; adjusted EBITDA margin near Certara's corporate average by end 2025.
- Certara reiterates 2024 revenue, adjusted EBITDA margin (31-33%), and adjusted diluted EPS guidance from May 7 earnings call.
- Acquisition expands Certara's drug discovery biosimulation portfolio; long-term partnership with Chemaxon.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1827090/000110465924078581/0001104659-24-078581-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1827090/000110465924078581/tm2418257d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-078581

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer